KCCQ Approved by FDA for Regulatory Submissions for Heart Failure Drugs

19 April 2020 - 15:07

Following up its prior approval of the KCCQ as a primary endpoint for labeling claims for heart failure devices, the FDA has also approved the KCCQ as a primary endpoint for heart failure medications.

John Spertus, MPH, MD, author of the KCCQ, states: “We are gratified by the FDA’s continuing recognition of the KCCQ’s important value in validating the impact of heart failure medications, and we hope that it improve the health status of all patients who receive them.”


No comments yet.

To comment, you must log in first.